AbbVie and Novartis Announce Fresh Rounds of U.S. Layoffs

By FieldPulse Staff · May 25, 2026

Tags: layoffs, AbbVie, Novartis, restructuring

The biopharma sector continues to face workforce reductions as AbbVie and Novartis slash headcount in their U.S. operations.

The pharmaceutical industry's restructuring wave shows no signs of slowing down in May 2026.

AbbVie and Novartis have both announced significant headcount reductions affecting their U.S.-based operations, as companies continue to tighten their belts amidst shifting market dynamics and patent cliffs.

AbbVie's Strategic Realignment AbbVie is reportedly cutting dozens of roles across various commercial and administrative functions.

While the company has not released a full breakdown of the affected divisions, insiders suggest that the move is part of a broader effort to optimize its portfolio following recent acquisitions.

For field reps, this often translates to territory consolidations and increased pressure on remaining staff to maintain coverage.

Novartis Continues Efficiency Drive Novartis is also moving forward with its planned efficiency drive, with fresh cuts reported in Maryland and other key hubs.

The company has been vocal about its transition to a 'pure-play' innovative medicines company, which has necessitated a leaner organizational structure.

These latest reductions are expected to take place over the coming months, with some roles being phased out as late as April 2027.

Impact on the Field Force For the pharma sales community, these announcements are a stark reminder of the volatility in the current job market.

While some companies are in a hiring spree for new launches, others are aggressively trimming legacy teams.

Adaptability and a strong track record in high-growth therapeutic areas remain the best defense for reps navigating these uncertain times.